nodes	percent_of_prediction	percent_of_DWPC	metapath
Indinavir—CYP3A5—Beclomethasone—psoriasis	0.038	0.0507	CbGbCtD
Indinavir—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0343	0.0458	CbGbCtD
Indinavir—ABCC1—Cyclosporine—psoriasis	0.0309	0.0412	CbGbCtD
Indinavir—SLCO1A2—Prednisolone—psoriasis	0.0308	0.0411	CbGbCtD
Indinavir—ABCC2—Mycophenolate mofetil—psoriasis	0.0302	0.0403	CbGbCtD
Indinavir—SLCO1A2—Hydrocortisone—psoriasis	0.0292	0.039	CbGbCtD
Indinavir—SLCO1A2—Prednisone—psoriasis	0.0291	0.0388	CbGbCtD
Indinavir—SLCO1A2—Cyclosporine—psoriasis	0.0276	0.0368	CbGbCtD
Indinavir—SLCO1B1—Cyclosporine—psoriasis	0.026	0.0347	CbGbCtD
Indinavir—ABCC2—Cyclosporine—psoriasis	0.0229	0.0305	CbGbCtD
Indinavir—SLCO1A2—Dexamethasone—psoriasis	0.0182	0.0242	CbGbCtD
Indinavir—CYP2D6—Hydroxyurea—psoriasis	0.0176	0.0235	CbGbCtD
Indinavir—ABCC1—Methotrexate—psoriasis	0.0163	0.0218	CbGbCtD
Indinavir—CYP3A7—Hydrocortisone—psoriasis	0.0162	0.0216	CbGbCtD
Indinavir—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0162	0.0216	CbGbCtD
Indinavir—CYP3A7—Cyclosporine—psoriasis	0.0153	0.0204	CbGbCtD
Indinavir—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0153	0.0204	CbGbCtD
Indinavir—CYP3A5—Mycophenolate mofetil—psoriasis	0.0151	0.0202	CbGbCtD
Indinavir—ABCC2—Dexamethasone—psoriasis	0.0151	0.0201	CbGbCtD
Indinavir—SLCO1A2—Methotrexate—psoriasis	0.0146	0.0195	CbGbCtD
Indinavir—CYP2C19—Cholecalciferol—psoriasis	0.0141	0.0188	CbGbCtD
Indinavir—SLCO1B1—Methotrexate—psoriasis	0.0138	0.0184	CbGbCtD
Indinavir—CYP3A4—Calcitriol—psoriasis	0.0132	0.0176	CbGbCtD
Indinavir—CYP3A5—Hydrocortisone—psoriasis	0.0121	0.0162	CbGbCtD
Indinavir—ABCC2—Methotrexate—psoriasis	0.0121	0.0161	CbGbCtD
Indinavir—CYP2C9—Cholecalciferol—psoriasis	0.0117	0.0156	CbGbCtD
Indinavir—CYP3A5—Cyclosporine—psoriasis	0.0115	0.0153	CbGbCtD
Indinavir—CYP2D6—Cholecalciferol—psoriasis	0.0107	0.0143	CbGbCtD
Indinavir—CYP3A4—Methoxsalen—psoriasis	0.0103	0.0137	CbGbCtD
Indinavir—CYP3A7—Dexamethasone—psoriasis	0.0101	0.0134	CbGbCtD
Indinavir—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0101	0.0134	CbGbCtD
Indinavir—ABCB1—Mycophenolate mofetil—psoriasis	0.00983	0.0131	CbGbCtD
Indinavir—CYP2C19—Prednisone—psoriasis	0.00974	0.013	CbGbCtD
Indinavir—CYP2C19—Cyclosporine—psoriasis	0.00924	0.0123	CbGbCtD
Indinavir—ABCB1—Betamethasone—psoriasis	0.00844	0.0113	CbGbCtD
Indinavir—ABCB1—Prednisolone—psoriasis	0.00833	0.0111	CbGbCtD
Indinavir—ABCB1—Hydrocortisone—psoriasis	0.00789	0.0105	CbGbCtD
Indinavir—ABCB1—Prednisone—psoriasis	0.00786	0.0105	CbGbCtD
Indinavir—CYP2C9—Cyclosporine—psoriasis	0.00768	0.0103	CbGbCtD
Indinavir—CYP3A5—Dexamethasone—psoriasis	0.00754	0.0101	CbGbCtD
Indinavir—ABCB1—Cyclosporine—psoriasis	0.00745	0.00995	CbGbCtD
Indinavir—CYP2D6—Cyclosporine—psoriasis	0.00702	0.00937	CbGbCtD
Indinavir—CYP3A4—Cholecalciferol—psoriasis	0.0068	0.00907	CbGbCtD
Indinavir—CYP2C19—Dexamethasone—psoriasis	0.00608	0.00812	CbGbCtD
Indinavir—CYP3A4—Mycophenolate mofetil—psoriasis	0.00589	0.00786	CbGbCtD
Indinavir—CYP3A4—Triamcinolone—psoriasis	0.00589	0.00786	CbGbCtD
Indinavir—CYP2C9—Dexamethasone—psoriasis	0.00506	0.00675	CbGbCtD
Indinavir—CYP3A4—Betamethasone—psoriasis	0.00506	0.00675	CbGbCtD
Indinavir—CYP3A4—Prednisolone—psoriasis	0.00499	0.00666	CbGbCtD
Indinavir—ABCB1—Dexamethasone—psoriasis	0.00491	0.00655	CbGbCtD
Indinavir—CYP3A4—Hydrocortisone—psoriasis	0.00473	0.00631	CbGbCtD
Indinavir—CYP3A4—Prednisone—psoriasis	0.00471	0.00629	CbGbCtD
Indinavir—CYP2D6—Dexamethasone—psoriasis	0.00462	0.00617	CbGbCtD
Indinavir—CYP3A4—Cyclosporine—psoriasis	0.00447	0.00596	CbGbCtD
Indinavir—ABCB1—Methotrexate—psoriasis	0.00394	0.00526	CbGbCtD
Indinavir—CYP3A4—Dexamethasone—psoriasis	0.00294	0.00393	CbGbCtD
Indinavir—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.000688	0.054	CbGpPWpGaD
Indinavir—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00062	0.0486	CbGpPWpGaD
Indinavir—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00057	0.0447	CbGpPWpGaD
Indinavir—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000565	0.0444	CbGpPWpGaD
Indinavir—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000532	0.0417	CbGpPWpGaD
Indinavir—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000497	0.039	CbGpPWpGaD
Indinavir—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000384	0.0302	CbGpPWpGaD
Indinavir—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000353	0.0277	CbGpPWpGaD
Indinavir—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00035	0.0275	CbGpPWpGaD
Indinavir—ABCB1—Allograft Rejection—IL22—psoriasis	0.000301	0.0236	CbGpPWpGaD
Indinavir—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000286	0.0224	CbGpPWpGaD
Indinavir—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000282	0.0221	CbGpPWpGaD
Indinavir—ABCC2—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000265	0.0208	CbGpPWpGaD
Indinavir—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000249	0.0195	CbGpPWpGaD
Indinavir—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000231	0.0182	CbGpPWpGaD
Indinavir—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000231	0.0181	CbGpPWpGaD
Indinavir—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000206	0.0162	CbGpPWpGaD
Indinavir—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000204	0.016	CbGpPWpGaD
Indinavir—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000167	0.0131	CbGpPWpGaD
Indinavir—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00016	0.0125	CbGpPWpGaD
Indinavir—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000157	0.0124	CbGpPWpGaD
Indinavir—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000152	0.0119	CbGpPWpGaD
Indinavir—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000147	0.0115	CbGpPWpGaD
Indinavir—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000145	0.0114	CbGpPWpGaD
Indinavir—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000145	0.0114	CbGpPWpGaD
Indinavir—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000144	0.0113	CbGpPWpGaD
Indinavir—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000129	0.0102	CbGpPWpGaD
Indinavir—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000125	0.00977	CbGpPWpGaD
Indinavir—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000123	0.00965	CbGpPWpGaD
Indinavir—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000121	0.00952	CbGpPWpGaD
Indinavir—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000119	0.00934	CbGpPWpGaD
Indinavir—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000118	0.00926	CbGpPWpGaD
Indinavir—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000106	0.00832	CbGpPWpGaD
Indinavir—ABCC1—S1P1 pathway—VEGFA—psoriasis	0.000103	0.00812	CbGpPWpGaD
Indinavir—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	9.59e-05	0.00753	CbGpPWpGaD
Indinavir—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	9.47e-05	0.00743	CbGpPWpGaD
Indinavir—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	9.26e-05	0.00727	CbGpPWpGaD
Indinavir—CYP3A5—Biological oxidations—CYP2S1—psoriasis	8.89e-05	0.00697	CbGpPWpGaD
Indinavir—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	8.77e-05	0.00688	CbGpPWpGaD
Indinavir—ABCC2—NRF2 pathway—TGFA—psoriasis	7.94e-05	0.00623	CbGpPWpGaD
Indinavir—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.78e-05	0.0061	CbGpPWpGaD
Indinavir—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	7.67e-05	0.00602	CbGpPWpGaD
Indinavir—Dizziness—Mycophenolic acid—psoriasis	7.48e-05	0.000314	CcSEcCtD
Indinavir—Paraesthesia—Prednisolone—psoriasis	7.48e-05	0.000314	CcSEcCtD
Indinavir—Malnutrition—Prednisone—psoriasis	7.42e-05	0.000312	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Hydrocortisone—psoriasis	7.41e-05	0.000311	CcSEcCtD
Indinavir—Hyperhidrosis—Triamcinolone—psoriasis	7.41e-05	0.000311	CcSEcCtD
Indinavir—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	7.39e-05	0.0058	CbGpPWpGaD
Indinavir—Feeling abnormal—Mycophenolate mofetil—psoriasis	7.36e-05	0.000309	CcSEcCtD
Indinavir—Insomnia—Hydrocortisone—psoriasis	7.36e-05	0.000309	CcSEcCtD
Indinavir—Paraesthesia—Hydrocortisone—psoriasis	7.3e-05	0.000307	CcSEcCtD
Indinavir—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.3e-05	0.000307	CcSEcCtD
Indinavir—Urticaria—Cyclosporine—psoriasis	7.27e-05	0.000305	CcSEcCtD
Indinavir—Myalgia—Betamethasone—psoriasis	7.25e-05	0.000305	CcSEcCtD
Indinavir—Myalgia—Dexamethasone—psoriasis	7.25e-05	0.000305	CcSEcCtD
Indinavir—Body temperature increased—Cyclosporine—psoriasis	7.24e-05	0.000304	CcSEcCtD
Indinavir—Abdominal pain—Cyclosporine—psoriasis	7.24e-05	0.000304	CcSEcCtD
Indinavir—Anxiety—Betamethasone—psoriasis	7.23e-05	0.000304	CcSEcCtD
Indinavir—Anxiety—Dexamethasone—psoriasis	7.23e-05	0.000304	CcSEcCtD
Indinavir—Vomiting—Mycophenolic acid—psoriasis	7.19e-05	0.000302	CcSEcCtD
Indinavir—Discomfort—Dexamethasone—psoriasis	7.16e-05	0.000301	CcSEcCtD
Indinavir—Discomfort—Betamethasone—psoriasis	7.16e-05	0.000301	CcSEcCtD
Indinavir—Dyspepsia—Hydrocortisone—psoriasis	7.16e-05	0.000301	CcSEcCtD
Indinavir—Haemoglobin—Methotrexate—psoriasis	7.16e-05	0.000301	CcSEcCtD
Indinavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.15e-05	0.00561	CbGpPWpGaD
Indinavir—Rash—Mycophenolic acid—psoriasis	7.13e-05	0.0003	CcSEcCtD
Indinavir—Dermatitis—Mycophenolic acid—psoriasis	7.13e-05	0.000299	CcSEcCtD
Indinavir—Pain—Prednisolone—psoriasis	7.12e-05	0.000299	CcSEcCtD
Indinavir—Hepatitis—Methotrexate—psoriasis	7.12e-05	0.000299	CcSEcCtD
Indinavir—Haemorrhage—Methotrexate—psoriasis	7.12e-05	0.000299	CcSEcCtD
Indinavir—Urticaria—Mycophenolate mofetil—psoriasis	7.09e-05	0.000298	CcSEcCtD
Indinavir—Headache—Mycophenolic acid—psoriasis	7.09e-05	0.000298	CcSEcCtD
Indinavir—Decreased appetite—Hydrocortisone—psoriasis	7.07e-05	0.000297	CcSEcCtD
Indinavir—Pharyngitis—Methotrexate—psoriasis	7.07e-05	0.000297	CcSEcCtD
Indinavir—Body temperature increased—Mycophenolate mofetil—psoriasis	7.06e-05	0.000297	CcSEcCtD
Indinavir—Abdominal pain—Mycophenolate mofetil—psoriasis	7.06e-05	0.000297	CcSEcCtD
Indinavir—Urinary tract disorder—Methotrexate—psoriasis	7.03e-05	0.000295	CcSEcCtD
Indinavir—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.02e-05	0.000295	CcSEcCtD
Indinavir—Fatigue—Hydrocortisone—psoriasis	7.01e-05	0.000295	CcSEcCtD
Indinavir—Vision blurred—Prednisone—psoriasis	6.99e-05	0.000294	CcSEcCtD
Indinavir—Urethral disorder—Methotrexate—psoriasis	6.98e-05	0.000293	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.98e-05	0.000293	CcSEcCtD
Indinavir—Pain—Hydrocortisone—psoriasis	6.96e-05	0.000292	CcSEcCtD
Indinavir—Anaphylactic shock—Betamethasone—psoriasis	6.95e-05	0.000292	CcSEcCtD
Indinavir—Oedema—Dexamethasone—psoriasis	6.95e-05	0.000292	CcSEcCtD
Indinavir—Anaphylactic shock—Dexamethasone—psoriasis	6.95e-05	0.000292	CcSEcCtD
Indinavir—Oedema—Betamethasone—psoriasis	6.95e-05	0.000292	CcSEcCtD
Indinavir—Insomnia—Triamcinolone—psoriasis	6.93e-05	0.000291	CcSEcCtD
Indinavir—Ill-defined disorder—Prednisone—psoriasis	6.88e-05	0.000289	CcSEcCtD
Indinavir—Paraesthesia—Triamcinolone—psoriasis	6.88e-05	0.000289	CcSEcCtD
Indinavir—CYP2C19—Biological oxidations—CYP2S1—psoriasis	6.87e-05	0.00539	CbGpPWpGaD
Indinavir—Feeling abnormal—Prednisolone—psoriasis	6.86e-05	0.000288	CcSEcCtD
Indinavir—Anaemia—Prednisone—psoriasis	6.85e-05	0.000288	CcSEcCtD
Indinavir—Shock—Dexamethasone—psoriasis	6.84e-05	0.000287	CcSEcCtD
Indinavir—Shock—Betamethasone—psoriasis	6.84e-05	0.000287	CcSEcCtD
Indinavir—Dyspnoea—Triamcinolone—psoriasis	6.83e-05	0.000287	CcSEcCtD
Indinavir—Nervous system disorder—Dexamethasone—psoriasis	6.82e-05	0.000286	CcSEcCtD
Indinavir—Nervous system disorder—Betamethasone—psoriasis	6.82e-05	0.000286	CcSEcCtD
Indinavir—Agitation—Prednisone—psoriasis	6.82e-05	0.000286	CcSEcCtD
Indinavir—Thrombocytopenia—Betamethasone—psoriasis	6.81e-05	0.000286	CcSEcCtD
Indinavir—Thrombocytopenia—Dexamethasone—psoriasis	6.81e-05	0.000286	CcSEcCtD
Indinavir—Angioedema—Prednisone—psoriasis	6.78e-05	0.000285	CcSEcCtD
Indinavir—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	6.78e-05	0.00532	CbGpPWpGaD
Indinavir—Hypersensitivity—Cyclosporine—psoriasis	6.74e-05	0.000283	CcSEcCtD
Indinavir—Dyspepsia—Triamcinolone—psoriasis	6.74e-05	0.000283	CcSEcCtD
Indinavir—Erythema multiforme—Methotrexate—psoriasis	6.73e-05	0.000283	CcSEcCtD
Indinavir—Nausea—Mycophenolic acid—psoriasis	6.72e-05	0.000282	CcSEcCtD
Indinavir—Hyperhidrosis—Dexamethasone—psoriasis	6.72e-05	0.000282	CcSEcCtD
Indinavir—Hyperhidrosis—Betamethasone—psoriasis	6.72e-05	0.000282	CcSEcCtD
Indinavir—Feeling abnormal—Hydrocortisone—psoriasis	6.7e-05	0.000282	CcSEcCtD
Indinavir—Malaise—Prednisone—psoriasis	6.69e-05	0.000281	CcSEcCtD
Indinavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.68e-05	0.00524	CbGpPWpGaD
Indinavir—Vertigo—Prednisone—psoriasis	6.66e-05	0.00028	CcSEcCtD
Indinavir—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	6.66e-05	0.00523	CbGpPWpGaD
Indinavir—Gastrointestinal pain—Hydrocortisone—psoriasis	6.65e-05	0.000279	CcSEcCtD
Indinavir—Syncope—Prednisone—psoriasis	6.65e-05	0.000279	CcSEcCtD
Indinavir—Anorexia—Dexamethasone—psoriasis	6.63e-05	0.000278	CcSEcCtD
Indinavir—Anorexia—Betamethasone—psoriasis	6.63e-05	0.000278	CcSEcCtD
Indinavir—Urticaria—Prednisolone—psoriasis	6.62e-05	0.000278	CcSEcCtD
Indinavir—Fatigue—Triamcinolone—psoriasis	6.6e-05	0.000277	CcSEcCtD
Indinavir—Hypersensitivity—Mycophenolate mofetil—psoriasis	6.58e-05	0.000276	CcSEcCtD
Indinavir—Asthenia—Cyclosporine—psoriasis	6.57e-05	0.000276	CcSEcCtD
Indinavir—Pain—Triamcinolone—psoriasis	6.55e-05	0.000275	CcSEcCtD
Indinavir—Loss of consciousness—Prednisone—psoriasis	6.52e-05	0.000274	CcSEcCtD
Indinavir—Pruritus—Cyclosporine—psoriasis	6.48e-05	0.000272	CcSEcCtD
Indinavir—Urticaria—Hydrocortisone—psoriasis	6.46e-05	0.000272	CcSEcCtD
Indinavir—Immune system disorder—Methotrexate—psoriasis	6.43e-05	0.00027	CcSEcCtD
Indinavir—Body temperature increased—Hydrocortisone—psoriasis	6.43e-05	0.00027	CcSEcCtD
Indinavir—Abdominal pain—Hydrocortisone—psoriasis	6.43e-05	0.00027	CcSEcCtD
Indinavir—Asthenia—Mycophenolate mofetil—psoriasis	6.41e-05	0.000269	CcSEcCtD
Indinavir—Chills—Methotrexate—psoriasis	6.39e-05	0.000268	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.33e-05	0.000266	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Betamethasone—psoriasis	6.33e-05	0.000266	CcSEcCtD
Indinavir—CYP2D6—Biological oxidations—CYP2S1—psoriasis	6.32e-05	0.00496	CbGpPWpGaD
Indinavir—Pruritus—Mycophenolate mofetil—psoriasis	6.32e-05	0.000265	CcSEcCtD
Indinavir—Arthralgia—Prednisone—psoriasis	6.31e-05	0.000265	CcSEcCtD
Indinavir—Myalgia—Prednisone—psoriasis	6.31e-05	0.000265	CcSEcCtD
Indinavir—Feeling abnormal—Triamcinolone—psoriasis	6.31e-05	0.000265	CcSEcCtD
Indinavir—Anxiety—Prednisone—psoriasis	6.29e-05	0.000264	CcSEcCtD
Indinavir—Alopecia—Methotrexate—psoriasis	6.29e-05	0.000264	CcSEcCtD
Indinavir—Insomnia—Betamethasone—psoriasis	6.29e-05	0.000264	CcSEcCtD
Indinavir—Insomnia—Dexamethasone—psoriasis	6.29e-05	0.000264	CcSEcCtD
Indinavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.27e-05	0.000263	CcSEcCtD
Indinavir—CYP2C9—Biological oxidations—CYP2S1—psoriasis	6.26e-05	0.00492	CbGpPWpGaD
Indinavir—Diarrhoea—Cyclosporine—psoriasis	6.26e-05	0.000263	CcSEcCtD
Indinavir—Paraesthesia—Betamethasone—psoriasis	6.24e-05	0.000262	CcSEcCtD
Indinavir—Paraesthesia—Dexamethasone—psoriasis	6.24e-05	0.000262	CcSEcCtD
Indinavir—Discomfort—Prednisone—psoriasis	6.24e-05	0.000262	CcSEcCtD
Indinavir—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	6.23e-05	0.00489	CbGpPWpGaD
Indinavir—Malnutrition—Methotrexate—psoriasis	6.2e-05	0.00026	CcSEcCtD
Indinavir—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	6.18e-05	0.00485	CbGpPWpGaD
Indinavir—Hypersensitivity—Prednisolone—psoriasis	6.14e-05	0.000258	CcSEcCtD
Indinavir—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	6.13e-05	0.00481	CbGpPWpGaD
Indinavir—Dyspepsia—Dexamethasone—psoriasis	6.12e-05	0.000257	CcSEcCtD
Indinavir—Dyspepsia—Betamethasone—psoriasis	6.12e-05	0.000257	CcSEcCtD
Indinavir—Diarrhoea—Mycophenolate mofetil—psoriasis	6.11e-05	0.000257	CcSEcCtD
Indinavir—Urticaria—Triamcinolone—psoriasis	6.09e-05	0.000256	CcSEcCtD
Indinavir—Dysgeusia—Methotrexate—psoriasis	6.07e-05	0.000255	CcSEcCtD
Indinavir—Body temperature increased—Triamcinolone—psoriasis	6.06e-05	0.000254	CcSEcCtD
Indinavir—Dizziness—Cyclosporine—psoriasis	6.05e-05	0.000254	CcSEcCtD
Indinavir—Oedema—Prednisone—psoriasis	6.05e-05	0.000254	CcSEcCtD
Indinavir—Anaphylactic shock—Prednisone—psoriasis	6.05e-05	0.000254	CcSEcCtD
Indinavir—Decreased appetite—Betamethasone—psoriasis	6.04e-05	0.000254	CcSEcCtD
Indinavir—Decreased appetite—Dexamethasone—psoriasis	6.04e-05	0.000254	CcSEcCtD
Indinavir—Gastrointestinal disorder—Betamethasone—psoriasis	6e-05	0.000252	CcSEcCtD
Indinavir—Gastrointestinal disorder—Dexamethasone—psoriasis	6e-05	0.000252	CcSEcCtD
Indinavir—Back pain—Methotrexate—psoriasis	6e-05	0.000252	CcSEcCtD
Indinavir—Hypersensitivity—Hydrocortisone—psoriasis	5.99e-05	0.000252	CcSEcCtD
Indinavir—Fatigue—Dexamethasone—psoriasis	5.99e-05	0.000252	CcSEcCtD
Indinavir—Fatigue—Betamethasone—psoriasis	5.99e-05	0.000252	CcSEcCtD
Indinavir—Shock—Prednisone—psoriasis	5.95e-05	0.00025	CcSEcCtD
Indinavir—Pain—Betamethasone—psoriasis	5.94e-05	0.00025	CcSEcCtD
Indinavir—Pain—Dexamethasone—psoriasis	5.94e-05	0.00025	CcSEcCtD
Indinavir—Nervous system disorder—Prednisone—psoriasis	5.94e-05	0.000249	CcSEcCtD
Indinavir—Dizziness—Mycophenolate mofetil—psoriasis	5.9e-05	0.000248	CcSEcCtD
Indinavir—Skin disorder—Prednisone—psoriasis	5.88e-05	0.000247	CcSEcCtD
Indinavir—Hyperhidrosis—Prednisone—psoriasis	5.85e-05	0.000246	CcSEcCtD
Indinavir—Vision blurred—Methotrexate—psoriasis	5.84e-05	0.000245	CcSEcCtD
Indinavir—Asthenia—Hydrocortisone—psoriasis	5.84e-05	0.000245	CcSEcCtD
Indinavir—Vomiting—Cyclosporine—psoriasis	5.82e-05	0.000245	CcSEcCtD
Indinavir—Rash—Cyclosporine—psoriasis	5.77e-05	0.000242	CcSEcCtD
Indinavir—Anorexia—Prednisone—psoriasis	5.77e-05	0.000242	CcSEcCtD
Indinavir—Dermatitis—Cyclosporine—psoriasis	5.77e-05	0.000242	CcSEcCtD
Indinavir—SLCO1A2—SLC-mediated transmembrane transport—CP—psoriasis	5.76e-05	0.00452	CbGpPWpGaD
Indinavir—Pruritus—Hydrocortisone—psoriasis	5.76e-05	0.000242	CcSEcCtD
Indinavir—Ill-defined disorder—Methotrexate—psoriasis	5.75e-05	0.000242	CcSEcCtD
Indinavir—Headache—Cyclosporine—psoriasis	5.73e-05	0.000241	CcSEcCtD
Indinavir—Anaemia—Methotrexate—psoriasis	5.73e-05	0.000241	CcSEcCtD
Indinavir—Feeling abnormal—Betamethasone—psoriasis	5.73e-05	0.000241	CcSEcCtD
Indinavir—Feeling abnormal—Dexamethasone—psoriasis	5.73e-05	0.000241	CcSEcCtD
Indinavir—ABCB1—Allograft Rejection—HLA-C—psoriasis	5.7e-05	0.00447	CbGpPWpGaD
Indinavir—Gastrointestinal pain—Dexamethasone—psoriasis	5.68e-05	0.000239	CcSEcCtD
Indinavir—Gastrointestinal pain—Betamethasone—psoriasis	5.68e-05	0.000239	CcSEcCtD
Indinavir—Vomiting—Mycophenolate mofetil—psoriasis	5.68e-05	0.000239	CcSEcCtD
Indinavir—ABCB1—Allograft Rejection—IL13—psoriasis	5.67e-05	0.00445	CbGpPWpGaD
Indinavir—Hypersensitivity—Triamcinolone—psoriasis	5.64e-05	0.000237	CcSEcCtD
Indinavir—Rash—Mycophenolate mofetil—psoriasis	5.63e-05	0.000237	CcSEcCtD
Indinavir—Dermatitis—Mycophenolate mofetil—psoriasis	5.62e-05	0.000236	CcSEcCtD
Indinavir—Headache—Mycophenolate mofetil—psoriasis	5.59e-05	0.000235	CcSEcCtD
Indinavir—Malaise—Methotrexate—psoriasis	5.59e-05	0.000235	CcSEcCtD
Indinavir—Vertigo—Methotrexate—psoriasis	5.57e-05	0.000234	CcSEcCtD
Indinavir—Diarrhoea—Hydrocortisone—psoriasis	5.57e-05	0.000234	CcSEcCtD
Indinavir—Urticaria—Betamethasone—psoriasis	5.52e-05	0.000232	CcSEcCtD
Indinavir—Urticaria—Dexamethasone—psoriasis	5.52e-05	0.000232	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Prednisone—psoriasis	5.51e-05	0.000232	CcSEcCtD
Indinavir—Dizziness—Prednisolone—psoriasis	5.51e-05	0.000231	CcSEcCtD
Indinavir—Asthenia—Triamcinolone—psoriasis	5.5e-05	0.000231	CcSEcCtD
Indinavir—Abdominal pain—Betamethasone—psoriasis	5.49e-05	0.000231	CcSEcCtD
Indinavir—Abdominal pain—Dexamethasone—psoriasis	5.49e-05	0.000231	CcSEcCtD
Indinavir—Body temperature increased—Dexamethasone—psoriasis	5.49e-05	0.000231	CcSEcCtD
Indinavir—Body temperature increased—Betamethasone—psoriasis	5.49e-05	0.000231	CcSEcCtD
Indinavir—Insomnia—Prednisone—psoriasis	5.47e-05	0.00023	CcSEcCtD
Indinavir—Nausea—Cyclosporine—psoriasis	5.44e-05	0.000228	CcSEcCtD
Indinavir—Paraesthesia—Prednisone—psoriasis	5.44e-05	0.000228	CcSEcCtD
Indinavir—Pruritus—Triamcinolone—psoriasis	5.42e-05	0.000228	CcSEcCtD
Indinavir—Cough—Methotrexate—psoriasis	5.41e-05	0.000227	CcSEcCtD
Indinavir—Dizziness—Hydrocortisone—psoriasis	5.38e-05	0.000226	CcSEcCtD
Indinavir—Dyspepsia—Prednisone—psoriasis	5.33e-05	0.000224	CcSEcCtD
Indinavir—Nausea—Mycophenolate mofetil—psoriasis	5.3e-05	0.000223	CcSEcCtD
Indinavir—Arthralgia—Methotrexate—psoriasis	5.28e-05	0.000222	CcSEcCtD
Indinavir—Myalgia—Methotrexate—psoriasis	5.28e-05	0.000222	CcSEcCtD
Indinavir—Chest pain—Methotrexate—psoriasis	5.28e-05	0.000222	CcSEcCtD
Indinavir—Decreased appetite—Prednisone—psoriasis	5.26e-05	0.000221	CcSEcCtD
Indinavir—Rash—Prednisolone—psoriasis	5.25e-05	0.000221	CcSEcCtD
Indinavir—Dermatitis—Prednisolone—psoriasis	5.25e-05	0.00022	CcSEcCtD
Indinavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.24e-05	0.00022	CcSEcCtD
Indinavir—Fatigue—Prednisone—psoriasis	5.22e-05	0.000219	CcSEcCtD
Indinavir—Headache—Prednisolone—psoriasis	5.22e-05	0.000219	CcSEcCtD
Indinavir—ABCB1—Allograft Rejection—IL17A—psoriasis	5.22e-05	0.00409	CbGpPWpGaD
Indinavir—Discomfort—Methotrexate—psoriasis	5.21e-05	0.000219	CcSEcCtD
Indinavir—Constipation—Prednisone—psoriasis	5.18e-05	0.000217	CcSEcCtD
Indinavir—Vomiting—Hydrocortisone—psoriasis	5.17e-05	0.000217	CcSEcCtD
Indinavir—Rash—Hydrocortisone—psoriasis	5.13e-05	0.000215	CcSEcCtD
Indinavir—Dermatitis—Hydrocortisone—psoriasis	5.12e-05	0.000215	CcSEcCtD
Indinavir—Headache—Hydrocortisone—psoriasis	5.1e-05	0.000214	CcSEcCtD
Indinavir—Dizziness—Triamcinolone—psoriasis	5.07e-05	0.000213	CcSEcCtD
Indinavir—Anaphylactic shock—Methotrexate—psoriasis	5.06e-05	0.000213	CcSEcCtD
Indinavir—Feeling abnormal—Prednisone—psoriasis	4.99e-05	0.00021	CcSEcCtD
Indinavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.99e-05	0.00391	CbGpPWpGaD
Indinavir—Asthenia—Betamethasone—psoriasis	4.99e-05	0.000209	CcSEcCtD
Indinavir—Asthenia—Dexamethasone—psoriasis	4.99e-05	0.000209	CcSEcCtD
Indinavir—Nervous system disorder—Methotrexate—psoriasis	4.96e-05	0.000208	CcSEcCtD
Indinavir—Thrombocytopenia—Methotrexate—psoriasis	4.95e-05	0.000208	CcSEcCtD
Indinavir—Gastrointestinal pain—Prednisone—psoriasis	4.95e-05	0.000208	CcSEcCtD
Indinavir—Nausea—Prednisolone—psoriasis	4.95e-05	0.000208	CcSEcCtD
Indinavir—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	4.93e-05	0.00387	CbGpPWpGaD
Indinavir—Pruritus—Dexamethasone—psoriasis	4.92e-05	0.000207	CcSEcCtD
Indinavir—Pruritus—Betamethasone—psoriasis	4.92e-05	0.000207	CcSEcCtD
Indinavir—Skin disorder—Methotrexate—psoriasis	4.91e-05	0.000206	CcSEcCtD
Indinavir—Hyperhidrosis—Methotrexate—psoriasis	4.89e-05	0.000205	CcSEcCtD
Indinavir—Vomiting—Triamcinolone—psoriasis	4.87e-05	0.000205	CcSEcCtD
Indinavir—ABCB1—Allograft Rejection—IL12B—psoriasis	4.85e-05	0.0038	CbGpPWpGaD
Indinavir—Nausea—Hydrocortisone—psoriasis	4.83e-05	0.000203	CcSEcCtD
Indinavir—Rash—Triamcinolone—psoriasis	4.83e-05	0.000203	CcSEcCtD
Indinavir—Dermatitis—Triamcinolone—psoriasis	4.83e-05	0.000203	CcSEcCtD
Indinavir—Anorexia—Methotrexate—psoriasis	4.82e-05	0.000203	CcSEcCtD
Indinavir—Urticaria—Prednisone—psoriasis	4.81e-05	0.000202	CcSEcCtD
Indinavir—Headache—Triamcinolone—psoriasis	4.8e-05	0.000202	CcSEcCtD
Indinavir—Abdominal pain—Prednisone—psoriasis	4.78e-05	0.000201	CcSEcCtD
Indinavir—Body temperature increased—Prednisone—psoriasis	4.78e-05	0.000201	CcSEcCtD
Indinavir—Diarrhoea—Dexamethasone—psoriasis	4.76e-05	0.0002	CcSEcCtD
Indinavir—Diarrhoea—Betamethasone—psoriasis	4.76e-05	0.0002	CcSEcCtD
Indinavir—ABCB1—Allograft Rejection—HLA-E—psoriasis	4.73e-05	0.00371	CbGpPWpGaD
Indinavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.66e-05	0.00366	CbGpPWpGaD
Indinavir—Musculoskeletal discomfort—Methotrexate—psoriasis	4.61e-05	0.000194	CcSEcCtD
Indinavir—Dizziness—Betamethasone—psoriasis	4.6e-05	0.000193	CcSEcCtD
Indinavir—Dizziness—Dexamethasone—psoriasis	4.6e-05	0.000193	CcSEcCtD
Indinavir—Insomnia—Methotrexate—psoriasis	4.58e-05	0.000192	CcSEcCtD
Indinavir—Nausea—Triamcinolone—psoriasis	4.55e-05	0.000191	CcSEcCtD
Indinavir—Paraesthesia—Methotrexate—psoriasis	4.54e-05	0.000191	CcSEcCtD
Indinavir—Dyspnoea—Methotrexate—psoriasis	4.51e-05	0.000189	CcSEcCtD
Indinavir—Somnolence—Methotrexate—psoriasis	4.5e-05	0.000189	CcSEcCtD
Indinavir—Hypersensitivity—Prednisone—psoriasis	4.46e-05	0.000187	CcSEcCtD
Indinavir—Dyspepsia—Methotrexate—psoriasis	4.45e-05	0.000187	CcSEcCtD
Indinavir—Vomiting—Betamethasone—psoriasis	4.42e-05	0.000186	CcSEcCtD
Indinavir—Vomiting—Dexamethasone—psoriasis	4.42e-05	0.000186	CcSEcCtD
Indinavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.41e-05	0.00346	CbGpPWpGaD
Indinavir—Decreased appetite—Methotrexate—psoriasis	4.4e-05	0.000185	CcSEcCtD
Indinavir—Rash—Dexamethasone—psoriasis	4.38e-05	0.000184	CcSEcCtD
Indinavir—Rash—Betamethasone—psoriasis	4.38e-05	0.000184	CcSEcCtD
Indinavir—Dermatitis—Dexamethasone—psoriasis	4.38e-05	0.000184	CcSEcCtD
Indinavir—Dermatitis—Betamethasone—psoriasis	4.38e-05	0.000184	CcSEcCtD
Indinavir—Gastrointestinal disorder—Methotrexate—psoriasis	4.37e-05	0.000183	CcSEcCtD
Indinavir—Fatigue—Methotrexate—psoriasis	4.36e-05	0.000183	CcSEcCtD
Indinavir—Headache—Betamethasone—psoriasis	4.35e-05	0.000183	CcSEcCtD
Indinavir—Headache—Dexamethasone—psoriasis	4.35e-05	0.000183	CcSEcCtD
Indinavir—Asthenia—Prednisone—psoriasis	4.34e-05	0.000182	CcSEcCtD
Indinavir—Pain—Methotrexate—psoriasis	4.33e-05	0.000182	CcSEcCtD
Indinavir—Pruritus—Prednisone—psoriasis	4.28e-05	0.00018	CcSEcCtD
Indinavir—SLC22A1—SLC-mediated transmembrane transport—CP—psoriasis	4.21e-05	0.0033	CbGpPWpGaD
Indinavir—Feeling abnormal—Methotrexate—psoriasis	4.17e-05	0.000175	CcSEcCtD
Indinavir—Diarrhoea—Prednisone—psoriasis	4.14e-05	0.000174	CcSEcCtD
Indinavir—Gastrointestinal pain—Methotrexate—psoriasis	4.14e-05	0.000174	CcSEcCtD
Indinavir—CYP3A4—Biological oxidations—CYP2S1—psoriasis	4.13e-05	0.00324	CbGpPWpGaD
Indinavir—Nausea—Betamethasone—psoriasis	4.13e-05	0.000173	CcSEcCtD
Indinavir—Nausea—Dexamethasone—psoriasis	4.13e-05	0.000173	CcSEcCtD
Indinavir—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	4.07e-05	0.0032	CbGpPWpGaD
Indinavir—Urticaria—Methotrexate—psoriasis	4.02e-05	0.000169	CcSEcCtD
Indinavir—Dizziness—Prednisone—psoriasis	4e-05	0.000168	CcSEcCtD
Indinavir—Body temperature increased—Methotrexate—psoriasis	4e-05	0.000168	CcSEcCtD
Indinavir—Abdominal pain—Methotrexate—psoriasis	4e-05	0.000168	CcSEcCtD
Indinavir—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	3.96e-05	0.00311	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	3.92e-05	0.00307	CbGpPWpGaD
Indinavir—Vomiting—Prednisone—psoriasis	3.85e-05	0.000162	CcSEcCtD
Indinavir—Rash—Prednisone—psoriasis	3.82e-05	0.00016	CcSEcCtD
Indinavir—Dermatitis—Prednisone—psoriasis	3.81e-05	0.00016	CcSEcCtD
Indinavir—Headache—Prednisone—psoriasis	3.79e-05	0.000159	CcSEcCtD
Indinavir—Hypersensitivity—Methotrexate—psoriasis	3.73e-05	0.000157	CcSEcCtD
Indinavir—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	3.64e-05	0.00286	CbGpPWpGaD
Indinavir—Asthenia—Methotrexate—psoriasis	3.63e-05	0.000152	CcSEcCtD
Indinavir—Nausea—Prednisone—psoriasis	3.6e-05	0.000151	CcSEcCtD
Indinavir—Pruritus—Methotrexate—psoriasis	3.58e-05	0.00015	CcSEcCtD
Indinavir—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.56e-05	0.0028	CbGpPWpGaD
Indinavir—ABCB1—Allograft Rejection—IL10—psoriasis	3.54e-05	0.00278	CbGpPWpGaD
Indinavir—Diarrhoea—Methotrexate—psoriasis	3.46e-05	0.000145	CcSEcCtD
Indinavir—ABCB1—Allograft Rejection—IL4—psoriasis	3.45e-05	0.00271	CbGpPWpGaD
Indinavir—ABCB1—Allograft Rejection—HLA-B—psoriasis	3.37e-05	0.00265	CbGpPWpGaD
Indinavir—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	3.37e-05	0.00264	CbGpPWpGaD
Indinavir—Dizziness—Methotrexate—psoriasis	3.35e-05	0.000141	CcSEcCtD
Indinavir—Vomiting—Methotrexate—psoriasis	3.22e-05	0.000135	CcSEcCtD
Indinavir—Rash—Methotrexate—psoriasis	3.19e-05	0.000134	CcSEcCtD
Indinavir—Dermatitis—Methotrexate—psoriasis	3.19e-05	0.000134	CcSEcCtD
Indinavir—Headache—Methotrexate—psoriasis	3.17e-05	0.000133	CcSEcCtD
Indinavir—SLCO1A2—Metabolism—NDUFA5—psoriasis	3.15e-05	0.00247	CbGpPWpGaD
Indinavir—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	3.14e-05	0.00246	CbGpPWpGaD
Indinavir—ABCB1—Allograft Rejection—HLA-A—psoriasis	3.12e-05	0.00245	CbGpPWpGaD
Indinavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.07e-05	0.00241	CbGpPWpGaD
Indinavir—Nausea—Methotrexate—psoriasis	3e-05	0.000126	CcSEcCtD
Indinavir—SLCO1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.94e-05	0.00231	CbGpPWpGaD
Indinavir—SLCO1A2—Transmembrane transport of small molecules—CP—psoriasis	2.93e-05	0.0023	CbGpPWpGaD
Indinavir—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	2.85e-05	0.00224	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—NDUFA5—psoriasis	2.84e-05	0.00222	CbGpPWpGaD
Indinavir—SLCO1A2—Transmembrane transport of small molecules—CARM1—psoriasis	2.79e-05	0.00219	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—NDUFA5—psoriasis	2.69e-05	0.00211	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—CYP2S1—psoriasis	2.68e-05	0.0021	CbGpPWpGaD
Indinavir—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	2.67e-05	0.00209	CbGpPWpGaD
Indinavir—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.64e-05	0.00207	CbGpPWpGaD
Indinavir—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	2.63e-05	0.00207	CbGpPWpGaD
Indinavir—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	2.54e-05	0.002	CbGpPWpGaD
Indinavir—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	2.51e-05	0.00197	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.51e-05	0.00197	CbGpPWpGaD
Indinavir—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	2.5e-05	0.00196	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—NDUFA5—psoriasis	2.47e-05	0.00194	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—CYP2S1—psoriasis	2.41e-05	0.00189	CbGpPWpGaD
Indinavir—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	2.39e-05	0.00187	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—NDUFA5—psoriasis	2.3e-05	0.00181	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—CYP2S1—psoriasis	2.29e-05	0.0018	CbGpPWpGaD
Indinavir—SLC22A1—Transmembrane transport of small molecules—CP—psoriasis	2.14e-05	0.00168	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—CYP2S1—psoriasis	2.1e-05	0.00165	CbGpPWpGaD
Indinavir—ABCB1—Allograft Rejection—IFNG—psoriasis	2.08e-05	0.00164	CbGpPWpGaD
Indinavir—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.08e-05	0.00163	CbGpPWpGaD
Indinavir—SLC22A1—Transmembrane transport of small molecules—CARM1—psoriasis	2.04e-05	0.0016	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—CYP2S1—psoriasis	1.96e-05	0.00154	CbGpPWpGaD
Indinavir—ABCB1—Allograft Rejection—CXCL8—psoriasis	1.94e-05	0.00152	CbGpPWpGaD
Indinavir—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.82e-05	0.00143	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—NDUFA5—psoriasis	1.79e-05	0.0014	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.6e-05	0.00125	CbGpPWpGaD
Indinavir—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.57e-05	0.00124	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—CYP2S1—psoriasis	1.52e-05	0.00119	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.4e-05	0.0011	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—NDUFA5—psoriasis	1.38e-05	0.00108	CbGpPWpGaD
Indinavir—ABCB1—Allograft Rejection—TNF—psoriasis	1.35e-05	0.00106	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—NDUFA5—psoriasis	1.35e-05	0.00106	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.34e-05	0.00105	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—CARM1—psoriasis	1.31e-05	0.00103	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.29e-05	0.00101	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—NDUFA5—psoriasis	1.27e-05	0.000997	CbGpPWpGaD
Indinavir—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.26e-05	0.000991	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—NDUFA5—psoriasis	1.26e-05	0.000989	CbGpPWpGaD
Indinavir—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.25e-05	0.000984	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.22e-05	0.00096	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.2e-05	0.000942	CbGpPWpGaD
Indinavir—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.2e-05	0.000938	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—CARM1—psoriasis	1.18e-05	0.000924	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—CYP2S1—psoriasis	1.18e-05	0.000922	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.17e-05	0.000922	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—CYP2S1—psoriasis	1.15e-05	0.0009	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—CARM1—psoriasis	1.12e-05	0.000878	CbGpPWpGaD
Indinavir—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.1e-05	0.000864	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—CYP2S1—psoriasis	1.08e-05	0.000848	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—CYP2S1—psoriasis	1.07e-05	0.000841	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.05e-05	0.000821	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—CARM1—psoriasis	1.03e-05	0.000806	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—CARM1—psoriasis	9.56e-06	0.00075	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.89e-06	0.000698	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.56e-06	0.000672	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—NDUFA5—psoriasis	8.31e-06	0.000652	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—CAT—psoriasis	8.05e-06	0.000631	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.77e-06	0.00061	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—CARM1—psoriasis	7.42e-06	0.000582	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—CAT—psoriasis	7.24e-06	0.000568	CbGpPWpGaD
Indinavir—ABCC1—Disease—HLA-A—psoriasis	7.2e-06	0.000565	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—CYP2S1—psoriasis	7.07e-06	0.000554	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—CAT—psoriasis	6.88e-06	0.00054	CbGpPWpGaD
Indinavir—ABCC1—Disease—APOE—psoriasis	6.72e-06	0.000527	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.66e-06	0.000522	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—CAT—psoriasis	6.32e-06	0.000496	CbGpPWpGaD
Indinavir—ABCC1—Disease—NOS2—psoriasis	6.26e-06	0.000491	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—APOE—psoriasis	6.25e-06	0.000491	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.16e-06	0.000483	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—CAT—psoriasis	5.88e-06	0.000461	CbGpPWpGaD
Indinavir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.87e-06	0.000461	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—CARM1—psoriasis	5.74e-06	0.00045	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—APOE—psoriasis	5.63e-06	0.000442	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.61e-06	0.000441	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—CARM1—psoriasis	5.6e-06	0.00044	CbGpPWpGaD
Indinavir—SLCO1A2—Metabolism—PPARG—psoriasis	5.45e-06	0.000427	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.36e-06	0.000421	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—APOE—psoriasis	5.35e-06	0.00042	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—CARM1—psoriasis	5.28e-06	0.000414	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—CARM1—psoriasis	5.23e-06	0.000411	CbGpPWpGaD
Indinavir—ABCC1—Disease—TYK2—psoriasis	5.13e-06	0.000402	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—APOE—psoriasis	4.91e-06	0.000385	CbGpPWpGaD
Indinavir—ABCC1—Metabolism—PPARG—psoriasis	4.9e-06	0.000385	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.89e-06	0.000384	CbGpPWpGaD
Indinavir—SLCO1B1—Metabolism—PPARG—psoriasis	4.66e-06	0.000365	CbGpPWpGaD
Indinavir—ABCC1—Disease—CD4—psoriasis	4.64e-06	0.000364	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—APOE—psoriasis	4.57e-06	0.000358	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—CAT—psoriasis	4.57e-06	0.000358	CbGpPWpGaD
Indinavir—CYP3A7—Metabolism—PPARG—psoriasis	4.27e-06	0.000335	CbGpPWpGaD
Indinavir—SLC22A1—Metabolism—PPARG—psoriasis	3.98e-06	0.000312	CbGpPWpGaD
Indinavir—ABCC1—Disease—STAT3—psoriasis	3.59e-06	0.000282	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—APOE—psoriasis	3.55e-06	0.000278	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—CAT—psoriasis	3.53e-06	0.000277	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—CARM1—psoriasis	3.45e-06	0.000271	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—CAT—psoriasis	3.44e-06	0.00027	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—CAT—psoriasis	3.25e-06	0.000255	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—CAT—psoriasis	3.22e-06	0.000253	CbGpPWpGaD
Indinavir—CYP3A5—Metabolism—PPARG—psoriasis	3.09e-06	0.000242	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—APOE—psoriasis	2.74e-06	0.000215	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—APOE—psoriasis	2.68e-06	0.00021	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—APOE—psoriasis	2.52e-06	0.000198	CbGpPWpGaD
Indinavir—ABCC1—Disease—IL6—psoriasis	2.51e-06	0.000197	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—APOE—psoriasis	2.5e-06	0.000196	CbGpPWpGaD
Indinavir—CYP2C19—Metabolism—PPARG—psoriasis	2.39e-06	0.000187	CbGpPWpGaD
Indinavir—ABCB1—Metabolism—PPARG—psoriasis	2.33e-06	0.000183	CbGpPWpGaD
Indinavir—CYP2D6—Metabolism—PPARG—psoriasis	2.2e-06	0.000172	CbGpPWpGaD
Indinavir—CYP2C9—Metabolism—PPARG—psoriasis	2.18e-06	0.000171	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—CAT—psoriasis	2.12e-06	0.000167	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—APOE—psoriasis	1.65e-06	0.000129	CbGpPWpGaD
Indinavir—CYP3A4—Metabolism—PPARG—psoriasis	1.44e-06	0.000113	CbGpPWpGaD
